Cisplatin in cancer therapy: molecular mechanisms of action

S Dasari, PB Tchounwou - European journal of pharmacology, 2014 - Elsevier
Cisplatin, cisplatinum, or cis-diamminedichloroplatinum (II), is a well-known
chemotherapeutic drug. It has been used for treatment of numerous human cancers …

Molecular mechanisms of cisplatin resistance in cervical cancer

H Zhu, H Luo, W Zhang, Z Shen, X Hu… - Drug design …, 2016 - Taylor & Francis
Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year
survival is only 10%–20%. Chemotherapy is considered as the standard treatment for …

Molecular mechanisms of cisplatin resistance

L Galluzzi, L Senovilla, I Vitale, J Michels, I Martins… - Oncogene, 2012 - nature.com
Platinum-based drugs, and in particular cis-diamminedichloroplatinum (II)(best known as
cisplatin), are employed for the treatment of a wide array of solid malignancies, including …

Cisplatin: mode of cytotoxic action and molecular basis of resistance

ZH Siddik - Oncogene, 2003 - nature.com
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity
against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its …

Cellular processing of platinum anticancer drugs

D Wang, SJ Lippard - Nature reviews Drug discovery, 2005 - nature.com
Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in
cancer chemotherapy. Platinum–DNA adducts, which are formed following uptake of the …

Cellular responses to Cisplatin‐induced DNA damage

A Basu, S Krishnamurthy - Journal of nucleic acids, 2010 - Wiley Online Library
Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid
tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging …

[HTML][HTML] Cellular landscaping of cisplatin resistance in cervical cancer

R Bhattacharjee, T Dey, L Kumar, S Kar… - Biomedicine & …, 2022 - Elsevier
Cervical cancer (CC) caused by human papillomavirus (HPV) is one of the largest causes of
malignancies in women worldwide. Cisplatin is one of the widely used drugs for the …

ERK1/2 MAP kinases in cell survival and apoptosis

Z Lu, S Xu - IUBMB life, 2006 - Wiley Online Library
ERK1/2 is an important subfamily of mitogen‐activated protein kinases that control a broad
range of cellular activities and physiological processes. ERK1/2 can be activated transiently …

[HTML][HTML] Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway

IW Achkar, N Abdulrahman, H Al-Sulaiti… - Journal of translational …, 2018 - Springer
Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers.
However, treatment with cisplatin is associated with drug resistance and several adverse …

Biochemical mechanisms of cisplatin cytotoxicity

V Cepeda, MA Fuertes, J Castilla… - Anti-Cancer Agents …, 2007 - ingentaconnect.com
Since the discovery by Rosenberg and collaborators of the antitumor activity of cisplatin 35
years ago, three platinum antitumor drugs (cisplatin, carboplatin and oxaliplatin) have …